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Abstract
Background: We have previously identified Semaphorin 6a (Sema6A) as an upregulated gene product in a gene expression
screen in cortical ischemia [1]. Semaphorin 6a was regulated during the recovery phase following ischemia in the cortex.
Semaphorin 6a is a member of the superfamily of semaphorins involved in axon guidance and other functions. We
hypothesized that the upregulation indicates a crucial role of this molecule in post-stroke rewiring of the brain. Here we
have tested this hypothesis by overexpressing semaphorin 6a in the cortex by microinjection of a modified AAV2-virus. A
circumscribed cortical infarct was induced, and the recovery of rats monitored for up to 4 weeks using a well-established
test battery (accelerated rotarod training paradigm, cylinder test, adhesive tape removal). We observed a significant
improvement in post-ischemic recovery of animals injected with the semaphorin 6a virus versus animals treated with a
control virus. We conclude that semaphorin 6a overexpressed in the cortex enhances recovery after cerebral ischemia.
Semaphorin 6a may represent a novel therapeutic candidate for the treatment of chronic stroke.
Citation: Rogalewski A, Dittgen T, Klugmann M, Kirsch F, Kru ¨ger C, et al. (2010) Semaphorin 6A Improves Functional Recovery in Conjunction with Motor Training
after Cerebral Ischemia. PLoS ONE 5(5): e10737. doi:10.1371/journal.pone.0010737
Editor: Christoph Kleinschnitz, Julius-Maximilians-Universita ¨tW u ¨rzburg, Germany
Received September 23, 2009; Accepted April 8, 2010; Published May 20, 2010
Copyright:  2010 Rogalewski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors’ work is a collaboration of the Sygnis Bioscience AG Heidelberg (Molecular Neurology), University of Muenster (Dept. of Neurology), and
University of Mainz (Inst. for Physiological Chemistry and Pathobiochemistry) without any further funding. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Schneider@Sygnis.de (AS); Wolf.Schaebitz@evkb.de (WRS)
. These authors contributed equally to this work.
¤ Current address: Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany
Introduction
Stroke is a major health problem in industrialized societies.
Despite numerous attempts at developing acute stroke therapies
aimed at minimizing acute infarct development, the only approved
therapy so far is recombinant tissue plasminogen activator (rtPA).
In recent years, the attention of the stroke community has
therefore also put increased emphasis on understanding processes
of post-stroke recovery, and their potential exploitability for
therapeutic purposes.
The brain has a remarkable ability to adapt to changes after
stroke. Mechanisms that contribute to this plasticity are re-
mapping and expansion of cortical areas to neighboring regions of
functional motor cortex areas after injury [2–4], and reorganiza-
tion of ipsilateral cortical regions distant from the injury [5]. The
correlates of these plastic changes are changes in neuronal
networks, mediated by the generation of new neurons (neurogen-
esis) [6,7], changes in dendritic and synaptic morphology [8], and
changes in long-distance connectivity, requiring axonal outgrowth
and pathfinding.
On a search for molecular determinants of those processes we
have conducted a gene expression study in the photothrombotic
model and searched for differentially expressed genes in the ipsi-
and contralateral homotopic cortex [1]. One of the regulated
genes appeared highly interesting in the context of post-stroke re-
organization of neuronal networks after injury and axonal
pathfinding to define new connections. This was a member of
the semaphorin family of axonal pathfinding genes, Semaphorin
6A (Sema6A). This gene was induced ipsilaterally starting 48 h
post ischemia, and increased in expression further at 21 d after
ischemia (by quantitative PCR the regulation was determined as
approximately 2-fold at 48 h, and 3-fold after 21 d in the
ipsilateral cortex) [1]. At 21 d there was also significant
upregulation detectable in the contralateral homotopic cortex
(app. 2.5-fold). This induction on the mRNA level could be
confirmed on the protein level by immunohistochemistry: At 48 h
and 21 d, there was strong periinfarct expression of Semaphorin
VIa in neurons, while induction on the contralateral homotopic
cortex was only detected at 21 d. This regulation pattern suggested
involvement in long-term plasticity processes in the periinfarct and
homotopic contralateral cortex.
Semaphorins are involved in many processes in development,
including cell migration, axon guidance, or dendritogenesis [9].
Transmembrane semaphorins of class 6 are important in vivo
mediators of axon guidance and cell migration in different parts of
the brain. Sema6A is characterized by an extracellular semaphorin
domain, a transmembrane domain, and a long cytoplasmic
domain [10]. There is evidence that these transmembrane
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as receptors, also due to the presence of the long cytoplasmic tail
harbouring an Evl domain. Sema6A can repel sympathetic and
dorsal root ganglion axons in vitro [11] suggesting that it fulfills the
functions of an axonal guidance signal.
Sema6A was identified in a gene-trap approach to find genes
involved in axonal pathfinding [12]. The most striking phenotype
of the Sema6A knock-out that was observed in this study was a
defect in thalamocortical projections in homozygous k.o. animals
[12]. In the cerebellum, Sema6A is involved in migration of
granule cells [13]. Here, the receptor PlxA2 seems to be the
responsible counterpart of Sema6A.
Recently, a striking defect in the building of the corticospinal
tract (CST) has been described in Sema6A mutants [14]. This
function seems to require the PlxnA4.
Here we have studied the effects of enhancing the expression of
Sema6A in the recovery phase after cerebral cortical ischemia by
AAV2-mediated gene transfer to the cortex.
Materials and Methods
Ischemic model and virus injection
24 Animals were anesthetized with an intraperitoneal injection
of xylazine hydrochloride (Bayer, Leverkusen Germany) and
ketamine hydrochloride (WDT, Garbsen, Germany). A PE-50
polyethylene tube was inserted into the right femoral artery for
continuous monitoring of mean arterial blood pressure, and blood
gases. During the experiment rectal temperature was monitored
and maintained at 37uC by a thermostatically controlled heating
pad (Fo ¨hr Medical Intruments, Germany).
Photothrombotic ischemia was induced in the rat parietal cortex
[15]. Animals were placed in a stereotaxic frame, and the scalp
was incised for exposure of the skull surface. For illumination, a
fiber-optic bundle with a 1.5-mm aperture was placed stereotax-
ically onto the skull 0.5 mm ventral to the bregma and 4 mm
lateral from the midline on the right side. The skull was
illuminated with a cold, white light beam (150 W) for 25 minutes.
During the first 2 minutes of illumination, the dye rose bengal
(0.133 mL/kg body weight, 10 mg/mL saline) was injected
intravenously. After surgery, the catheters were removed, and
the animals were allowed to recover from the anesthesia and given
food and water ad libitum.
The day following induction of cerebral ischemia virus was
injected stereotactically at 3 positions in the ipsi- and contralateral
hemisphere. The following coordinates were used: 3 mm lateral
and 3.5 mm ventral to the bregma; 5.5 mm lateral and 0.5 mm
ventral to the bregma and 4 mm lateral and 3.5 mm dorsal to the
bregma. Injections were done by an experimenter blinded to the
identity of the virus.
AAV vector production
HEK 293 cells are plated 24 hours before transfection in
complete DMEM. About 70% confluent cells are transfected with
12.5 mg AAV plasmid, 25 mg pFdelta6, 6.25 mg pRV1, 6.25
pH21, 330 ml 2.5 M CaCl2 and 2.4 ml H2O per 15 cm dish as
follows(Klugmann, et al., 2005): The transfection mix is filtered
through a 0.2 mm syringe filter. Under vigorous vortexing 13 ml of
26HeBs buffer is added and precipitate is allowed to form for
2 min. 5 ml of the transfection solution is gently added to each
plate dropwise. 16 hours after transfection, the medium is
removed and replaced with 25 ml of fresh DMEM. 60–65 hours
after transfection cells are gently washed with 25 ml warm 16PBS
and harvested in 25 ml 16PBS using a cell scraper. Cells are
pelleted at 800 g for 10 min, resuspended in 10 ml 150 mM
NaCl, 20 mM Tris pH 8.0. Sodium deoxycholate (Sigma
#D5670) is added to a final concentration of 0.5% and Benzonase
endonuclease (Sigma #E1014) to a final concentration of 50 U/
ml. Solution is mixed thoroughly, incubated at 37uC for 1 h. Cell
debris is removed by centrifugation at 3000g615min, 4uC.
Heparin columns (1 ml HiTrap Heparin columns, Sigma #5-
4836) are pre-equilibrated with 10 ml 150 mM NaCl, 20 mM Tris
pH 8.0. The column is loaded at 1 ml/min. The column is
washed with 20 ml 100 mM NaCl, 20 mM Tris pH 8.0 at 1 ml/
min, 1 ml 200 mM NaCl, 20 mM Tris pH 8.0 and 161m l
300 mM NaCl, 20 mM Tris pH 8.0. The virus is eluted in 1.5 ml
400 mM NaCl, 20 mM Tris pH 8.0, 3 ml 450 mM NaCl, 20 mM
Tris pH 8.0 and 1.5 ml 500 mM NaCl, 20 mM Tris pH 8.0. The
virus containing eluate is concentrated using self-contained
AMICON ULTRA- 4 (100000 MWCO; Millipore; CatNo.
UFC810024) filters at 2000 g for 2 min. Afterwards it is sterilized
by filtration through a 13 mm 0.2 mm syringe filter. 10 ml purified
vector are analysed on a Coomassie protein gel for purity.
Figure 1. Map of the Sema6A-AAV2 construct, and persistence
of expression. (A) The N-terminally 3xFLAG-tagged rat Sema6A was
cloned behind the CMV/chicken beta actin promoter. (B) PCR for
semaphorin-FLAG mRNA in the brain 35 days post injection of the virus.
Shown is an agarose gel electrophoresis for amplimers specific for virus-
originated Sema6a mRNA 35 days post injection in brain hemispheres.
For the detection of AAV-3x FLAG-Semaphorin 6A nested PCR primers
were used giving a final PCR product of 223 bp. The marker is a 100 bp-
ladder. lane 1: (animal #22; Sema6A AAV2); lane 2: (animal #24;
Sema6A AAV2); lane 3: (animal #8; empty AAV2); lane 4: (animal #11;
empty AAV2); lane 5: positive control (AAV-3x FLAG-Semaphorin 6A
plasmid); lane 6: negative control (water).
doi:10.1371/journal.pone.0010737.g001
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Viral DNA is extracted by diluting 2 ml of virus stock in 10 ml
106 ABI buffer (500 mM KCl, 100 mM Tris pH 8.0, 50 mM
MgCl2)and86 ml sterile water.1 ml DNAseIisaddedandincubated
at 37uC for 30 min. DNAse is inactivated at 70uC for 10 min. 10 mg
of Proteinase K are added and the mixture is incubated for 1 hour
at 50uC. Proteinase K is inactivated at 95uC for 20 min. Viral DNA
is diluted 1:50 in PCR grade water. The titer of the virus is
determined by quantitavie PCR (Lightcycler, Roche Diagnostics) in
comparison to plasmids with known dilutions. The following
primers are used: WPRE for: GGC TGT TGG GCA CTG ACA
AT; WPRE rev: CCG AAG GGA CGT AGC AGA AG; CBA titre
for: TAT CAT ATG CCA AGT ACG CCC C; CBA titre rev:
GGG CCA TTT ACC GTC ATT GA.
RT-PCR
RNA of brains was isolated using the acidic phenol extraction
protocol followed by QIAGEN RNeasy Mini Kit purification
according to the manufacturer’s recommendations. cDNA was
synthesized from 5 mg total RNA using oligo-dT primers and
Superscript II Reverse Transcriptase (Invitrogen Corp.).
For the detection of the AAV-3x FLAG-semaphorin 6A a
nested PCR strategy was pursued using the following primers:
semaphorin_788_s (GAC TGA CCG CGT TAC TCC CAC
AGG TGA) and semaphorin_1510_as (TCG AGC AGC AAT
GTA GAG GGT TCT GTTC) for the first PCR giving a product
of 722 bp (56uC annealing, 35 cycles). The second PCR primer
pair - semaphorin_3X_Flag_1154_sense (ACC ATG GAC TAC
AAA GAC CAT GAC GG) and semaphorin_1377_as (ATA CTG
ATC GGC TCA GAA TCT TCT GGG) - generated the final
PCR product of 223 bp (56uC annealing, 35 cycles).
Behavioral Testing
All animals were operated on and tested in parallel (1 animal
per group at once). In all animals, behavioral tests were performed
before (baseline) and 3, 17, 24, and 31 days after ischemia by a
blinded investigator. For Rotarod tests, the animals were not
trained before ischemia. From day 6 onward rats were trained for
a total of 10 days, with 2 days break in between, in an accelerated
Rotarod training paradigm [16]. Rats were placed on an
accelerating Rotarod cylinder, and the time the animals remained
on the Rotarod was measured. Speed was increased from 4 to
40 rpm within 5 minutes. The trial ended if the animal fell off the
rungs or gripped the device and spun around for 2 consecutive
revolutions without attempting to walk on the rungs. An arbitrary
time limit of 500 seconds was set for the rats on the Rotarod
Figure 2. Schedule of the experimental setup. Photothrombotic ischemia was induced in the rat parietal cortex at day 0. 1 day after induction
of ischemia, AAV2 was injected at 3 positions both on the ipsi- and contralateral hemisphere. Adhesive tape removal and cylinder tests were done at
day 3, day 20, 27 and 34. Rotarod training was performed at day 6 to 10, day 13 to 17, day 24, and day 31.
doi:10.1371/journal.pone.0010737.g002
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day the rats received 10 training sessions.
The adhesive removal test was done both before (baseline) and
3, 20, and 34 days after ischemia. Initially, 2 pieces of adhesive-
backed paper dots (113.1 mm
2) were used as bilateral tactile
stimuli on the dorsal paw of each forelimb. The time to remove
each stimulus from the forelimbs was recorded 3 trials per day for
each forepaw. Individual trials were separated by 5 minutes.
Before surgery, animals were trained for 3 days.
The cylinder test was done both before (baseline) and 3, 20, and
34 days after ischemia. The animals were not trained before
ischemia. The rats were placed in a transparent plexiglas cylinder
(20cm high, 20cm diameter) placed on a glass table for 5 minutes
and recorded on video. For analysis, the number of independent
placements of the forelimbs was measured over a time period of
30 seconds.
Experimental setup
All animal experiments followed ethical standards, and
protocols were approved by the respective government authorities.
Male Wistar rats (Charles River; 280 to 320 g) were randomly
assigned to groups with end points at day 31. Virus was injected 1
day following photothrombotic ischemia. Animals (n=12 per
group) were injected with either verum or vehicle virus by an
operator blinded to the treatment.
Statistics
Experiments were performed in a completely randomized and
blinded manner. The experimenter was blinded to the identity of
treatment at the time of the injection, and during the behavioural
evaluation. Statistical analyses were done using JMP 8.01 (SAS
Institute). A p value,0.05 was considered significant.
Results
Experimental setup
As expression tool for the semaphorin 6A protein we used the
adeno-associated virus serotype 2 (AAV 2). We chose this virus
Figure 3. AAV2-mediated semaphorin 6a overexpression
improves recovery over time as measured by Rotarod perfor-
mance. Rats were placed on an accelerating Rotarod cylinder, and the
time the animals remained on the Rotarod was measured. From day 6
onward rats were trained for a total of 10 days, with 2 days break in
between, in an accelerated rotarod training paradigm. Every training
day the rats received 10 training sessions. Animals that had received the
Sema6a AAV2 virus (blue line) performed significantly better over time
than animals that had received empty virus (red line) (repeated
measures ANOVA, p,0.05). Post hoc tests revealed significant
differences between groups from day 14 onward (p,0.05).
doi:10.1371/journal.pone.0010737.g003
Figure 4. Effects of the cylinder test and adhesive tape removal
test. (A) Cylinder test. (B) Adhesive removal task left. (C) Adhesive
removal task left. The adhesive removal and cylinder tests were done
both before (baseline) and 3, 20, and 34 days after ischemia. There was
a strong trend towards better performance of the Sema6A AAV2
injected animals (blue line) in the cylinder test (repeated measures
ANOVA, p=0.0752). Although the mean performance of Sema6A AAV2
injected rats in the adhesive tape removal appears better than control
animals, this difference was not significant.
doi:10.1371/journal.pone.0010737.g004
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of expression, the safety of the virus, and the potential applicability
as a human therapeutic vector [17]. This vector has been used in a
large number of studies addressing neurobiological questions
[18–22]. We cloned the rat semaphorin 6A open reading frame
(N-terminally 3X FLAG-tagged) after the cytomegalovirus en-
hancer/chicken b-actin promoter chicken beta actin (CBA)
promoter (Figure 1A). As control vectors, we packaged the
AAV2-plasmid without any coding sequence (AAV2-empty).
Injection of the virus resulted in expression of Semaphorin 6A at
least until the end of the experiment when we could detect virus-
originated Semaphorin 6A mRNA in the verum- but not in the
control-virus injected brains (31 days post injection; Figure 1B,
compare lanes 1 and 2 versus 3 and 4).
Photothrombotic ischemia was performed using intravenous
injection of bengal rose, and illumination of the cortical
sensorimotor frontpaw area with a laser (coordinates 4 mm lateral
and 0.5 mm ventral to the bregma). Semaphorin 6A AAV2 virus
or control virus was injected bilaterally 1 day following photo-
thrombotic ischemia at 3 sites per hemisphere (coordinates: 3 mm
lateral and 3.5 mm ventral to the bregma; 5.5 mm lateral and
0.5 mm ventral to the bregma; 4 mm lateral and 3.5 mm dorsal to
the bregma). These injection sites were targeted to the periis-
chemic region. 12 animals per group were injected by an operator
blinded to the virus identity. From day 6 onward rats were trained
for a total of 10 days in an accelerated rotarod training paradigm,
with 2 days break in between. Every training day the rats received
10 training sessions. The experimental setup scheme is given in
figure 2.
Semaphorin 6A overexpression improves poststroke
motor recovery
Animals were tested on an accelerating Rotarod at post-
operative days 6 to 10, 13 to 17, 24, and 31 (Figure 3). Overall
behavior of groups was different as judged by repeated measures
ANOVA (p,0.05). Post-hoc tests reveal significant differences
between groups starting at day 14, and staying significant
thereafter.
In the cylinder test we observed a strong trend towards better
performance of the group injected with the semaphorin 6a
expressing virus (repeated measures ANOVA, p=0.0752). This
trend was increasing with time from the operation (Figure 4A).
Performance in the adhesive tape removal test for the left or
right paw was not significantly different; however, the graph
suggests a trend to better performance starting day 3 post surgery
(Figure 4B and C).
In conclusion, Semaphorin6A overexpression led to a significant
and strong improvement in Rotarod performance, and to a strong
trend improvement in the cylinder test.
Discussion
Axonal pathfinding is an integral prerequisite for rewiring
neuronal networks that adapt to changed functional requirements.
The most well-known family of proteins involved in axonal
pathfinding are the semaphorins, that fall into eight classes of
membraneous or secreted proteins sharing a 500 amino acid so-
called sema domain, and guide growth cones by attraction or
repulsion (for review see [23,24]).
The only protein of the semaphorin class so far associated with
cerebral ischemia is Semaphorin 3A, which was reported to be
temporarily upregulated after MCAO [25], and induced after
14 d in the perilesional area of an infarct in the barrel cortex
together with its receptor neuropilin I [26]. Complicating potential
functions in post-stroke axonal pathfinding, Semaphorin 3A in the
adult brain is also clearly associated with neuronal apoptosis [27].
Here we have defined a beneficial role of overexpression of the
semaphorin Sema6A in the recovery phase after cortical ischemia.
Together with physical training we observed positive effects on
functional outcome. The clearest and significant effect was seen on
Rotarod performance over time. It may be that the power of the
Rotarod measurements was considerably higher compared to the
adhesive tape removal or cylinder test. Alternatively, the effect
may be strongest here since the physical training was also done on
the Rotarod, thus providing a very specific training for this
function. This may mean that the effect of Sema6A on plasticity is
strongest when the most concomitant activity training is done.
At present it is unclear what properties of Sema6A contribute to
the pro-recovery effect seen. One obvious possibility would be that
rewiring of the post-stroke brain is enhanced. It is however also
possible that Sema6a is somehow involved in targeting or
migration of neuronal stem cells activated by the ischemic event.
These questions put aside, we have defined here a novel player
in post-stroke recovery processes that is upregulated after ischemia
over a long time frame, and whose overexpression enhances
functional recovery.
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